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Title: Exploring knowledge of pre-eclampsia and views on a potential screening test 
in women with type 1 diabetes 
Abstract 
Objective 
To explore knowledge of pre-eclampsia and opinions on potential screening tests for 
pre-eclampsia in women with type 1 diabetes. 
Design 
A qualitative study using semi-structured interviews of women planning a pregnancy, 
currently pregnant or post-partum with experience of pre-eclampsia. 
Setting, Participants and Methods 
Eleven women with type 1 diabetes were recruited from a pre-pregnancy planning 
clinic or antenatal clinic. Semi-structured interviews were conducted with the women, 
asking a series of open-ended questions about their current knowledge of pre-
eclampsia and their views on screening for pre-eclampsia. Data analysis was 
conducted using inductive thematic analysis. 
Findings 
Four main themes were identified: Information, sources of stress, awareness and 
acceptability of screening. Generally, women’s knowledge of pre-eclampsia was 
limited. Most did not appear to be aware of their increased risk of developing the 
disease. Similarly, the majority of women were unaware as to why their blood 
pressure and urine were checked regularly. The introduction of a screening test for 
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pre-eclampsia was favoured, with only a small number of women raising concerns 
related to the screening tests. 
Conclusions 
Health care professionals need to raise awareness of pre-eclampsia in this high risk 
group. The introduction of a screening test for pre-eclampsia appears to be 
acceptable in this population, however, further research is required to validate these 
findings and also to explore the views of women in other high risk groups.  
Keywords 
Diabetes, pre-gestational, pregnancy, information, pre-eclampsia, screening 
Word count: 5,493; Abstract: 232
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Introduction 
Pre-eclampsia is a hypertensive disorder of pregnancy defined as new-onset 
hypertension accompanied by proteinuria, maternal organ dysfunction or foetal 
growth restriction after 20 weeks gestation (Tranquilli et al., 2014). It is associated 
with significant neonatal and maternal morbidity and mortality (Backes et al., 2011). 
Although currently the only effective treatment for pre-eclampsia is delivery, low-dose 
aspirin started in early pregnancy (~12-16 weeks) has been shown to reduce the risk 
of pre-eclampsia in women who are considered at high risk (Duley et al., 2007). 
During pregnancy, maternal characteristics are reviewed to assess the risk of pre-
eclampsia. Risk factors included age more 40 years, nulliparity, BMI greater than 30, 
history of pre-eclampsia and diabetes (English et al., 2015). In addition blood 
pressure and urinary protein levels are monitored regularly for signs of pre-eclampsia 
(NICE, 2016a). While recent National Institute for Health and Care Excellence (NICE) 
guidelines advocate the use of assays measuring angiogenic markers, such as 
Placental Growth Factor (PlGF) and soluble fms-like tyrosine kinase-1 (sFlt-1) ratios, 
to ‘rule-out’ pre-eclampsia in all women suspected of having the condition (NICE, 
2016b), there is currently no effective screening test to predict pre-eclampsia in 
clinical practice.   
Much research continues to focus on identification of accurate methods of predicting 
pre-eclampsia. Potential methods include the use of biochemical markers in blood 
and urine, biophysical measures, such as velocity indices obtained from ultrasound 
scans, and various combinations of these (O'Gorman et al., 2016; Poon and 
Nicolaides, 2014). However, very little research has explored the views of women on 
the acceptability of such tests. A study by Harris and colleagues ( 2014) assessed 
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the psychological effect of providing women with risk information for pre-eclampsia. 
The study reported that women perceived there was an advantage to knowing the 
risk, despite the lack of effective treatment. Women felt that this information allowed 
them to be more prepared and may even help them to recognise the symptoms 
earlier. However, it is likely that women will react differently to the outcome of a 
screening test due to their own perception of risk, which is not entirely based on 
medical diagnosis (Heaman et al., 2004). How women view their pregnancy will be 
affected by their perception of risk (Lee et al., 2014), with women labelled as high-
risk being negatively affected psychosocially (Stahl and Hundley, 2003).  It is of 
particular interest to determine if women with diabetes, who are already considered 
high-risk, feel that an additional test for risk is acceptable or if this leads to 
medicalisation of pregnancy as previously suggested (Harris et al., 2014).To date, 
there have been no studies which have explored the views of women on screening 
for pre-eclampsia prior to introduction of a screening test. In addition to this, the 
views of women with type 1 diabetes, who are at substantially increased risk of pre-
eclampsia, have not been explored. Therefore, the aim of this study was to provide 
insight into the knowledge of pre-eclampsia and views on implementation of a 
potential screening test for the condition in women with type 1 diabetes. 
Methods 
Participants 
Ethical approval was granted from the South-West Exeter Research Ethics 
Committee (REC Ref: 14/SW/1015) prior to commencement of the study. 
Participants were recruited via linkage with the specialist pre-pregnancy care clinic or 
the joint antenatal-metabolic clinic within the Belfast Health and Social Care trust 
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(BHSCT). Women were invited to participate if they were planning a pregnancy 
(nulliparous women only), currently pregnant or if they were up to 1 year post-
partum. Women were eligible if they were aged 18 years or over and had a diagnosis 
of pre-gestational type 1 diabetes. Exclusion criteria included poor understanding of 
written or spoken English due to limited resources to facilitate translation and serious 
adverse outcome in a previous pregnancy (i.e. malformation or stillbirth), as 
discussion around this topic may have been upsetting.  
Procedure 
All potential participants were identified and approached by a healthcare professional 
and given an information sheet and an invitation slip which they returned to the 
researcher if they were happy to be contacted. Post-natal women were mailed the 
invitation/permission slip and the information sheet, alongside a stamped addressed 
envelope. At least 48 hours elapsed between the participant giving consent and the 
researcher contacting them to discuss the study. Interviews were scheduled for a 
time and place that suited the participant. Interviews lasted approximately 30-45 
minutes, which included completion of consent forms, a background questionnaire 
and the interview. Participants were informed that interview would be audio recorded 
to allow for analysis to be conducted afterwards. Semi-structured interviews were 
conducted to allow the participants to introduce their own themes and ideas in 
relation to the topic, whilst ensuring the discussion remained relevant. Topic guides 
were used to guide the interviews and covered three main areas: advice for planning 
for pregnancy, knowledge about pre-eclampsia and screening for pre-eclampsia. For 
example, in relation to screening, women were asked ‘Currently, risks factors are the 
only way of assessing what risk you have of developing pre-eclampsia. What would 
your opinion be on the introduction of a screening test for pre-eclampsia? This test 
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may involve a blood test in combination with a more detailed scan and the risk 
factors that are currently used. The test could be delivered around 13 weeks (close 
to your current date) or 24 weeks’. It was deemed that women would have varying 
levels of knowledge in relation to pre-eclampsia so, if needed,  an information leaflet 
from Action on Pre-eclampsia (Action on Pre-eclampsia, 2015) was discussed with 
women prior to discussion around screening for pre-eclampsia, allowing for more 
relevant discussion. 
Data analysis 
Interview recordings were transcribed verbatim and analysed through inductive 
thematic analysis, as described by Braun and Clarke, 2006 (Braun and Clarke, 
2006). Six stages are described and are presented in Table 1. All transcripts were 
first read and re-read by A.C.W., with any comments/statements of interest being 
underlined to allow development of preliminary coding ideas. Transcripts were then 
reviewed and coded systematically. Codes and statements that were related to each 
code were extracted and tabulated, with similar codes being grouped into themes.  
Themes were reviewed and divided into sub-themes if needed. Themes and sub-
themes were discussed with a second researcher (V.A.H.) to ensure they reflected 
the data. 
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Results 
Demographics 
A total of twenty-one women were invited to participate in the study, with thirteen 
agreeing to participate. Of the nine women that were invited but did not participate, 
eight did not respond when contacted by the researcher and one woman stated a 
lack of time. Two of the thirteen women were excluded (due to adverse incidents in a 
previous pregnancy), thus eleven women participated. Table 2 shows characteristics 
of participants. Of the eleven women that participated, two were planning a 
pregnancy and nine were currently pregnant. Of women who were currently 
Table 1: Phases of thematic analysis as discussed by Braun and Clarke, 2006 (Braun 
and Clarke, 2006) 
 
Phase Description of process 
1. Familiarizing yourself with the data Transcribe the data, reading and re-reading 
the data, noting down initial ideas 
2. Generating initial codes Coding interesting features of the data in a 
systematic fashion across the entire data set, 
collating data relevant to each code 
3. Searching for themes Collating codes into potential themes, 
gathering all data relevant to each theme 
4. Reviewing themes Checking if the themes work in relation to 
coded extracts (level 1) and the entire data 
set (level 2), generating a thematic map of the 
analysis 
5. Defining and names themes Ongoing analysis to refine the specifics of 
each theme, and the overall story the analysis 
tells, generating clear definitions and names 
for each theme 
6. Producing the report The final opportunity for analysis. Selection of 
vivid, compelling examples, final analysis of 
selected extracts, relating back to the analysis 
of the research question and literature, 
producing a scholarly report of the analysis 
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pregnant, mean (SD) gestational age was 24.6 (8.8) weeks. No post-partum women 
who had experienced pre-eclampsia were recruited to the study. 
 
Themes 
Four main themes were identified from the thematic analysis: Women’s reflection on 
information received, sources of stress, women’s self-awareness of complications in 
pregnancy and factors affecting acceptability of screening. A thematic map was 
developed to demonstrate themes and sub-themes that emerged from the data 
(Figure 1).  
 
 
Table 2: Demographic information of participants 
Characteristic Mean (SD) (n=11) 
Status 
Planning pregnancy 
Currently pregnant 
Post-partum 
 
2 
9 
0 
Maternal age (years) 30.2 (5.4) 
BMI (kg/m2) 28.6 (3.7) 
Years in full time education 16.3 (3.0) 
Diabetes duration 17.3 (11.1) 
Ethnicity 
White 
 
11 (100%) 
Marital status 
Never married 
Married 
Co-habit 
 
2 (18%) 
7 (64%) 
2 (18%) 
Current smoker 2 (18%) 
Nulliparous 10 (91%) 
Planned pregnancy 7 (64%) 
Received pre-pregnancy counselling 7 (64%) 
Data are presented as mean (SD) and n (%)  
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Women’s reflection on information received 
The first theme consisted of two subthemes: Receiving further information and 
discussion and perceived lack of information received from healthcare professionals. 
 
Receiving further information and discussion 
Women generally stated that more information about conditions during pregnancy 
would be helpful, particularly if there were any risks involved, as is the case with pre-
eclampsia. Women often explained that they had sought further information from 
external sources, including the internet, books or friends: 
‘Well if there were any risks, yea I would like to know. I would prefer 
to be more aware of signs cause I have never heard of it to be 
Figure 1: Thematic map of themes and sub-themes emerging from the data 
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honest…if there were any risks I’d like to know.’  - Participant 001, 
currently pregnant 
‘I got a few pregnancy books and there was just a section on 
complications and pre-eclampsia was one of them.’ – Participant 011, 
currently pregnant 
One woman discussed how she felt about her appointments and believed that she 
did not have adequate time to ask questions as appointments were rushed, although 
she did appreciate that this was difficult as the clinic was very busy. She also stated 
that she liked to be involved in decisions about her care and would have preferred to 
discuss things further with or receive further information from her care team, 
particularly in relation to being prescribed aspirin: 
‘I like being involved you know? If you are going to be put on aspirin, I 
want to sort of talk about it, I don’t want to just go…I’m not one of 
these people who just go ok and just go on it. I’ll be like ok why and 
what’s it going to do…because they obviously have a reason to put 
you on it but…I’m probably not looking in the right places…there is 
probably something out there that supports it so it would be good 
yea. But it probably comes down to time.’ – Participant 008, currently 
pregnant 
Perceived lack of information received from healthcare professionals 
Women appeared to receive varying levels of information, although most women said 
they were well supported by their diabetes care team and felt well prepared for their 
pregnancy. It became apparent that information received by women both prior to and 
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during their pregnancy mainly centred on blood glucose targets and how this might 
affect their baby. Information around changing doses of insulin and monitoring blood 
sugars more frequently was also discussed. Most women did not recall receiving 
much other information: 
‘The only thing I received, because I was diabetic, was about blood 
sugar level control and that was pretty much it. That was really what it 
was focused around.’ – Participant 009, currently pregnant 
‘…but it was mainly just for bloods and how was your control. There 
was never really anything else.’ – Participant 013, currently pregnant 
Despite this, specific outcomes in relation to glycaemic control did not appear to be 
discussed. Women were asked if they received information about good glycaemic 
control reducing the risk of pre-eclampsia. The majority of women did not know this, 
but some did state that they assumed good control would be better overall: 
 ‘Like with a lot of things, they’ll say oh because you’ve got diabetes, 
you’re at high risk of this and higher risk of that but they don’t really 
tell you that if your blood sugar…your HbA1c is very controlled the 
risk really drops…’ – Participant 004, currently pregnant 
A number of women also stated that at their booking appointment, they were given 
leaflets or a ‘Pregnancy book’, which contained information about various conditions, 
but this was never verbally discussed with them. Additionally, women highlighted that 
timing of information may be important. Some stated that they received a lot of 
information at their booking appointment, and that it may be more helpful to receive it 
further into their pregnancy:  
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‘You were just handed the book and it was kind of like it’s in there, 
read it if you want, but I was never verbally told about it.’ – Participant 
013, currently pregnant 
‘yea, probably but then I think at your booking appointment you get 
told so much that it might be more beneficial to hear it a bit later on, a 
wee bit.’ Participant 009, currently pregnant 
Of women who were currently pregnant, only one woman recalled being told as to 
why her blood pressure and urine were being check regularly, with most being 
unaware as to why their blood pressure and urine was checked on a frequent basis: 
‘I obviously understood I was getting my blood pressure taken but I 
didn’t know specifically what they were looking for.’ – Participant 002, 
currently pregnant 
‘…he just told us that it had to be checked every so many weeks, 
every 6 weeks at least, but he didn’t really go into detail why.’ – 
Participant 004, currently pregnant 
In contrast, some women did discuss that they felt a little overwhelmed with 
information sometimes, and that there was a lot to take in so sometimes they may 
have forgotten what they were told: 
‘I got a lot of information so she probably has somewhere along the 
line…I think it’s all the negative stuff sticks in your head and 
everything else just kind of goes over.’ – Participant 004, currently 
pregnant 
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Sources of stress 
The second theme consisted of two sub-themes: stress relating to diabetes in 
pregnancy and stress surrounding result of pre-eclampsia screening test 
Stress relating to diabetes in pregnancy 
Stress related to a number of factors during pregnancy, ranging from discussing 
increased risks during pregnancy related to diabetes, to doubts about taking 
medications whilst pregnant, to how results of the potential screening test for pre-
eclampsia would affect them. 
Two women highlighted concern over taking tablets during pregnancy. As women 
with diabetes are considered high risk for pre-eclampsia, they are prescribed aspirin 
from 12 weeks onwards. These women recalled it being discussed and doubted if 
they should be going on medication during pregnancy: 
‘Yea, exactly! That was my main worry at the beginning, you taking 
another tablet on top of the folic acid and the pregnancy vitamins and 
stuff, you know, another tablet!’ – Participant 002, currently pregnant 
Women with diabetes are at an increased risk of a number of adverse outcomes and 
a number of women did recall being told this. However, this approach of being told 
the increased risk for multiple outcomes appeared to worry some women: 
‘I’m told I’m high risk for everything so I’ve pretty much just worried 
my entire pregnancy.’ – Participant 011, currently pregnant 
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Stress surrounding result of screening test for pre-eclampsia 
In relation to any future screening test for pre-eclampsia, it was suggested that the 
result of the test may cause potential stress. This issue was generally raised due to 
the lack of treatment available to women and so the value of knowing was 
questioned by some: 
‘I’m sort of in two minds because as you say, there’s not really a lot 
they can do with it once you have it so…in a way, it would be peace 
of mind to be checked but then once you have it, what can you do? 
It’s not like they can give you a tablet to make it go away and as you 
say, the only cure is delivery. So what are you going to do? Sit for the 
last couple of weeks and worry?’ – Participant 011, currently 
pregnant 
Although it was recognised that the result may be stressful, some women stated they 
would still prefer to know, even in terms of allowing them to take, what they deemed 
to be, helpful preventative measures: 
‘I would still like to know! Don’t get me wrong, I would be worried if 
there was more outcome of it but I would definitely like to know…it’s 
just for yourself and the baby to keep safe. I know you can’t do 
anything until the baby is delivered, but I would definitely like to know 
[…] just to see what they can do to help it or like myself with the 
diabetes, just to try and keep the bloods good…or maybe just do 
something that could help.’ – Participant 001, currently pregnant 
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Others stated if the test result was low risk, it would still be in their minds but it would 
be less worrying: 
 ‘You probably wouldn’t really consider it much, but I suppose if you 
had already been for that test, it would still always be in your mind, so 
if you did start having symptoms, you’d probably automatically think 
of it.’ – Participant 009, currently pregnant 
 
Women’s self-awareness of conditions in pregnancy 
Awareness consisted of two sub-themes: awareness of complications associated 
with diabetes and raising awareness of pre-eclampsia through testing. 
Awareness of complications associated with diabetes 
Women were very aware that having diabetes during pregnancy means that they 
were at high risk for a number of adverse outcomes and that pregnancy with 
diabetes was more complicated than a ‘healthy’ pregnancy: 
‘Well one, I’m diabetic so I knew there was going to be more 
complications involved…’ – Participant 007, planning pregnancy  
When asked if they were aware that having type 1 diabetes put them at an increased 
risk of pre-eclampsia, just over half of the women said that they were aware, which 
seemed to stem from when aspirin was prescribed to them: 
‘I think it was mentioned maybe 3 visits ago, just before the aspirin 
got prescribed to me. It was talked about then. I think that’s when I 
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first remember hearing the words pre-eclampsia.’ – Participant 002, 
currently pregnant 
With regard to awareness of signs and symptoms of pre-eclampsia, the response 
was mixed. Some women were able to list a number of symptoms, whilst others 
vaguely recalled a single symptom. Blood pressure was most often quoted as a sign, 
with only a small number of women knowing other symptoms like swelling and 
headaches. Sources of this kind of information also varied, and included healthcare 
professionals (i.e. obstetricians and general practitioner), friends and the internet: 
‘I know it’s blood pressure. They check for blood pressure, check 
your urine for protein and then after that, I just assume headaches.’ – 
Participant 008, currently pregnant 
Blood pressure, protein in your urine and swelling in your legs 
or…well particularly in your hands and face sometimes.’ – Participant 
010, currently pregnant 
Raising awareness of pre-eclampsia through testing 
In relation to screening for pre-eclampsia, women generally felt that screening would 
aid awareness of pre-eclampsia. It was perceived that the information received 
surrounding the screening test would allow women to be more aware of symptoms 
and to allow them to recognise them sooner: 
‘Yea, it maybe would then you could maybe…instead of waiting until 
your next appointment you could maybe phone somebody and get it 
checked out.’ – Participant 008, currently pregnant 
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Factors affecting acceptability of screening 
Most women stated that if the screening test was offered to them that they would 
take it. The majority of women felt that it would be better to know your risk of pre-
eclampsia, despite the fact that delivery is currently the only effective treatment: 
‘Yea but you still need to know…I think you’re better off knowing 
really.’ – Participant 007, planning pregnancy 
 ‘I’d rather know. I prefer that to the unknown. I like to know about 
things, to know what to expect or something.’ – Participant 009, 
currently pregnant 
A number of factors determined the acceptability of the test, and women’s opinions 
did differ in relation to these factors. The lack of treatment was mentioned as a 
limitation for some women, whilst others were unfazed about the lack of treatment: 
‘[If]  there was some preventative method or treatment…some option 
to delay things, then probably the screening would be more useful 
than whenever there isn’t a preventative thing and the only treatment 
if having the baby.’ – Participant 010, currently pregnant 
‘Well I think I would want it either way. I would want to know and 
then…well if there is a treatment, I want the treatment.’ – Participant 
007, planning pregnancy 
The method of testing also affected women’s opinions. There was little issue over the 
test if it consisted of something non-invasive, such as an extra blood test or an extra 
ultrasound scan. However, opinion changed if there were risks to the baby 
associated with screening. As women attending the joint antenatal-metabolic clinic 
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already have their blood taken every 2 weeks to monitor blood glucose control, they 
did not see an issue with someone taking additional blood to test it: 
‘Yea I would, I wouldn’t at all. Obviously I am giving blood every 2 
weeks anyway.’ – Participant 004, currently pregnant 
‘No, well if you’re going to be coming to appointments anyway and 
it’s just a case of getting something simple like that done, then I don’t 
really see that there should be any…like I wouldn’t be saying no to it.’ 
– Participant 013, currently pregnant  
Accuracy and reliability were also discussed as important factors in deciding whether 
the test should be offered or if women would take it. One woman intimated she would 
be happy to take the test, even if it was not 100% accurate. Another woman stated 
that the test should only be offered if it was reliable. Having the option of taking the 
test was also raised by some women. It was felt that not all women would want to 
know their risk and so should be allow to refuse the test, and if they were interested 
in knowing, then they should be able to opt to have it: 
‘I think the option would be good to be there, in the same way in your 
20 week scan you can get there anomaly check for that and then if 
they do find something, you can opt to have a deeper scan or not. I 
think that option should be left to you. I think definitely if it is offered 
but I think it should be left up to the mother if they want to take it or 
not.’ – Participant 011, currently pregnant  
In addition to this, most women were aware that the screening test may affect 
different women in different ways, highlighting that reaction would depend on 
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personality. Women were generally very understanding of the notion that while they 
may not be concerned about result the test, others may be: 
‘…would cause some people a bit of extra stress. It just depends on 
how each person deals with it…’ – Participant 005, planning 
pregnancy 
‘I’m not much of a worrier, whereas some people, that might make 
them worry the whole…you know?’ – Participant 009, currently 
pregnant 
It was also highlighted that it might be better know your risk of pre-eclampsia in the 
earlier stages of pregnancy. One woman also went on to talk about the possibility of 
using this test result to stratify women based on their risk, and whether or not they 
received preventative measures (i.e. aspirin). Another woman added to this and felt 
that it may be more beneficial to only screen women who were in the higher risk 
categories: 
‘And the other thing is like all these preventative measures, but I 
don’t think there is anything that says I am going to get it until I get it 
if you know what I mean? And maybe that would pick it up so you 
can have it quicker.’ – Participant 008, currently pregnant 
 ‘I think if you were to fall into the higher risk group, something should 
be…if there is something to be offered, maybe it should be offered to 
the higher risk category…Makes more sense to monitor more the 
higher risk…’ – Participant 013, currently pregnant 
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Women who were currently pregnant were also asked how they would like the 
outcome to be presented to them if the test was introduced. Answers were mixed, 
with the majority of women saying either as a percentage or a high/low risk. One 
woman highlighted that the percentage would be stressful: 
‘If I got told I was 90% chance, then I would worry! I know I’m high 
risk but there’s nothing screaming at you like you’re 90%, you’re 
going to get this.’ – Participant 008, currently pregnant 
In contrast to this, another woman felt that high/low risk was too vague and that a 
percentage would be much more helpful: 
‘I like detail so I would probably go for the percentage, because I find 
it quite irritating as a diabetic just to be told…to be fired into a high 
risk category for everything.’ – Participant 010, currently pregnant 
Only two ladies opted for a visual representation of results. One lady said she would 
prefer the visual result and felt this would be much more helpful on the whole to other 
women: 
‘I don’t think the format really matters but I think something visual 
over pages and pages of writing. Especially for people who maybe 
aren’t as academically minded as others that visual things are always 
that wee bit easier to look at and understand…’ – Participant 013, 
currently pregnant 
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Discussion 
Summary 
This is the first study to investigate opinions of women surrounding potential 
screening for pre-eclampsia in women with type 1 diabetes. Generally, women were 
accepting of a potential screening test being introduced, although some women did 
raise concerns over the lack of effective prophylaxis and if the test posed a risk to 
their baby. The majority of women were also unaware as to why their blood pressure 
and urine were being measured on a regular basis and also stated that more 
information regarding pre-eclampsia would be helpful. However, number of women 
did express feelings of being overwhelmed with information during their pregnancy.  
Interpretation 
Research into opinions on screening for pre-eclampsia is scarce. A previous study 
(Harris et al., 2014) investigated the psychological impact of receiving risk 
information about pre-eclampsia in women were screened for pre-eclampsia and 
given a high or low-risk diagnosis. The study reported that most women regarded the 
screening test as acceptable and would like to be offered it in subsequent 
pregnancies. Some women did question the value of the test in light of the fact that 
there is no effect prophylaxis but also highlighted that they felt that would be better 
able to recognise the symptoms of pre-eclampsia if they received a high-risk 
diagnosis. The current study similarly found that women with type 1 diabetes, who 
are already at an increased risk of developing pre-eclampsia, stated that they 
thought a predictive test for pre-eclampsia would be useful. They also stated that the 
test would be helpful in terms of awareness of symptoms and what the condition 
was. These results are similar to those from a survey conducted by the Pre-
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eclampsia Foundation, asking women about their opinions of screening for pre-
eclampsia (Preeclampsia Foundation, 2013). A total of 958 women responded, with 
88% of women who had a history of pre-eclampsia saying that an early screening 
test would be beneficial, even if it was imperfect. The survey also found that 74% of 
women without a history of pre-eclampsia believed that the test would be beneficial. 
There was also a common consensus that risk information was important to know, 
even if there was no preventative intervention.  
Women in the current study also stated that the test would be helpful in terms of 
awareness of symptoms and what the condition was, with many also stating that they 
were unaware of what pre-eclampsia was or had never heard of it. In contrast to this, 
further research from the Pre-eclampsia Foundation investigated the awareness of 
pre-eclampsia and found that although awareness was generally high, awareness of 
specific symptoms was low (Preeclampsia Foundation., 2014).Previous work by You 
and colleagues ( 2012b) suggested that women with pre-gestational diabetes had a 
better awareness of pre-eclampsia, as they were more likely to accurately define pre-
eclampsia than those without pre-gestational diabetes. However, results from the 
current study would suggest that knowledge of pre-eclampsia amongst women with 
diabetes is low. Some women did mention that they received leaflets or the 
‘Pregnancy book’ at their booking appointment. The ‘Pregnancy book’, that all 
women who are attending antenatal care should receive, contains information on 
signs and symptoms of pre-eclampsia (Department of Health., 2016). This may 
indicate that women simply did not read the information that they received which may 
highlight an issue surrounding the format of the information. A randomized controlled 
trial by You and colleagues ( 2012a) investigated the use of different formats of 
information for pre-eclampsia to improve patient knowledge of the condition. 
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Participants were assigned to receive no intervention, a pamphlet from the American 
College of Obstetricians and Gynaecologists (ACOG) or the novel graphics-based 
tool. Women who received the graphics based tool demonstrated superior 
knowledge of pre-eclampsia compared to women who received the stand ACOG 
pamphlet or nothing. Additionally, women in the study reported here highlighted that 
timing of information may be important. Some women stated that they received a lot 
of information at their booking appointment, and that it may be more helpful to 
receive it later in pregnancy. It is therefore possible that women simply were unable 
to  recall information due to the amount received at their booking appointment. 
Previous studies have shown that women with good blood glucose control, both prior 
to and during pregnancy, are at a reduced risk of pre-eclampsia, compared to those 
with poor glycaemic control (Cohen et al., 2014; Holmes et al., 2011). Despite this, 
the majority of women in the current study did not recall receiving information about 
the benefits of good glycaemic control on the risk of pre-eclampsia. This mirrors 
previous findings (Chuang et al., 2010; Spence et al., 2010) which found that women 
with diabetes, in particular nulliparous women, were aware that there are risks 
associated with diabetes in pregnancy but were not aware of specific risks. 
Additionally parous women with diabetes only reported knowing about the risk of a 
large baby and new-born glucose abnormalities. Also of note, women realised that 
importance of preconception care for management of their condition prior to 
pregnancy. It is therefore possible that women with diabetes are not being informed 
of specific risks (e.g. pre-eclampsia) in relation to their pregnancy by their healthcare 
professionals. 
The majority of women in this study stated that they were unaware as to why their 
blood pressure and urine were being measured on a regular basis. This is despite 
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the fact that current NICE guidelines for antenatal care state that women should be 
informed of the purpose of any test prior to it being performed (NICE, 2016a). 
However, a lack of information may relate to time pressures of staff within the 
department. The Patient Client Council (PCC) published a report in 2010, exploring 
patients’ views of maternity services in Northern Ireland (Patient Client Council., 
2010). The report found that patients felt that information (i.e. leaflets) was received 
at the first appointment without opportunity at a later stage to discuss the information 
or any concerns. Furthermore, patients cited that staff appeared to be under 
pressure and that more staff may improve the service received. This was similarly 
highlighted in the current study, with women stating they felt they did not have 
adequate time to discuss concerns or information and that their appointments were 
rushed. 
Strengths and weaknesses 
A major strength of this study was the format of semi-structured interviews for data 
collection. This approach allowed women to incorporate their own opinions and 
experiences whilst the conversation still remained relevant. Inclusion of both women 
who were currently pregnant and those who  were planning their first pregnancy 
allowed any potential differences in knowledge due to stage of pregnancy to be 
highlighted, as women who were planning their pregnancy would not have received 
any information during a previous pregnancy. Of the women who were currently 
pregnant, a wide range of gestational ages were included (range 16-37 weeks), 
giving rich data across the childbirth trajectory. It was recognised that women would 
have varying knowledge of pre-eclampsia, so to enhance discussion surrounding 
screening for pre-eclampsia, the APEC leaflet was discussed with women after 
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discussing their knowledge of pre-eclampsia and before discussion of screening 
tests. 
There was difficulty in recruiting women who had experienced pre-eclampsia 
previously, due to the small numbers of women with type 1 diabetes attending 
antenatal care, and even smaller numbers of those who went on to develop pre-
eclampsia. It was also only possible to recruit one woman who was multigravida, 
meaning that differences between information received across pregnancies could not 
be examined. Only women with type 1 diabetes were included, and may have 
differing opinions to women who are considered low risk during pregnancy and have 
less clinical contact. Additionally, only women of white ethnic origin participated and 
so views may not reflect women of other ethnic origins. Indeed, it has been 
highlighted that women from ethnic minorities are at higher risk of morbidity and 
mortality. It should also be noted that this study was only conducted on a single site 
and therefore may not represent views and opinions held in other areas. 
Conclusions 
Overall, women generally were accepting of the introduction of a potential screening 
test for pre-eclampsia. This is the first study to date to assess the opinions of women 
on the introduction of a screening test, prior to its implementation. As potential 
screening tests are currently being developed, it was important to explore the views 
of women about screening for pre-eclampsia, in light of the fact that there is no 
effective preventative treatment. The UK NSC currently does not recommend 
screening for pre-eclampsia, due to a lack of appropriate predictive tests or 
preventative treatment (United Kingdom National Screening Committee (UKNSC)., 
2010).  However, as research into more accurate predictive tests and preventative 
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treatments continue (Dorniak-Wall et al., 2014; Duhig and Shennan, 2011; Kenny et 
al., 2010; O'Gorman et al., 2016), a screening test for pre-eclampsia may be 
introduced into clinical practice in the foreseeable future. It was therefore essential to 
explore the views of women around potential screening to assess the impact that it 
may have. Further research into this and other high risk maternal populations should 
be conducted to validate these findings and also highlight views of other women.  
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